Drug Combination Details
| General Information of the Combination (ID: C17620) | |||||
|---|---|---|---|---|---|
| Name | Gambogic acid NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [2] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | Viable A549 cells (5*106/100 ul PBS per mouse) were mixed with 50% Matrigel, and then subcutaneously injected into the right flank of 7- to 8- week old male Balb/c nude mice. | |||||
| Experimental
Result(s) |
Suppression of NF-KappaB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP7 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p38 beta | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. | |||||
| Experiment 3 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| In-vivo Model | SKOV-3 cells (1*107 cells in 200 ll PBS per mouse) were injected subcutaneously on the right hind flank of mice. | |||||
| Experimental
Result(s) |
Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis. | |||||
